Session (CTI)

Issue: Antimicrobial resistance (AMR) poses a significant global public health threat, complicating infectious disease treatment, increasing morbidity and mortality, and escalating healthcare costs. Its emergence is largely driven by inappropriate antimicrobial use. Vaccination plays a critical role in combating AMR by preventing infectious diseases and thereby reducing antimicrobial usage. However, traditional economic evaluations often overlook these substantial public health benefits, primarily due to data gaps and technical challenges in quantifying them.Overview: This panel will explore the evaluation of the broader value of vaccines in combatting the global public health challenge of AMR, debating the need and approaches for evidence generation and methodological advancement. Dr. Huang will moderate the session and provide an overview of the global burden of AMR, summarize recent research on projecting AMR health economic burden of AMR, and highlight existing challenges and gaps (10 mins). Dr. Grijalva will examine key clinical sectors driving AMR development and transmission and discuss the public health implications of integrating vaccine strategies into AMR prevention efforts (15 mins). Dr. Elbasha will present a novel vaccine model, showcasing methodologies in quantifying population benefits of vaccines in AMR prevention and addressing uncertainties in resistance evolution. The case study will illustrate projected public health impacts in both high-income countries where antimicrobial overuse is prevalent, and low- and middle-income countries facing double challenges of antimicrobial shortage and rising resistance (15 mins). Dr. Drummond will discuss uncertainty assessment and model validations when demonstrating broader value of vaccines to decision makers and offer recommendations on future research (10 mins). The session will conclude with a moderated audience discussion, inviting attendees to share their views and insights.